Skip to main content

Table 2 Response rates & subgroup analysis

From: Bendamustine in patients with relapsed or refractory multiple myeloma

   

Subgroups dosage

 

Subgroups therapy mode

 
   

80-100 mg/m 2

120-150 mg/m 2

 

Monotherapy

+ Steroids

 

n = 39

  

n = 21

n = 18

p

n = 12

n = 27

p

PR

14 (1 vgPR)

36%

7

33%

7

38%

0.8

3

25%

11

40%

0.5

MR

7

18%

4

19%

3

17%

1.0

2

17%

5

19%

1.0

SD

10

26%

7

33%

3

17%

0.3

5

42%

5

19%

0.2

PD

8

20%

3

15%

5

28%

0.4

2

17%

6

22%

1.0

  1. vgPR very good partial remission; PR partial remission; MR Minor remission; SD stable disease; PD progressive disease